Ionic Liquids Shown to Break Bacterial Biofilm Layer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ionic Liquids Shown to Break Bacterial Biofilm Layer


Biofilm-protected bacteria account for some 80% of total bacterial infections in humans and are 50 to 1000 times more resistant to antibiotics than simpler bacterial infections. Biofilms often persist beneath an intact, healthy skin layer and the difficulty of their treatment is largely due to the outermost layer of the skin being a natural barrier for drug delivery.

A unique class of materials, known as ionic liquids, neutralizes biofilm-forming pathogens and delivers drugs through the skin. Studies show that in several cases, ionic liquid is more efficacious on a biofilm than a standard bleach treatment. This has excellent prospects for aiding antibiotic delivery to the pathogen through biofilm disruption and the ionic liquids themselves are quite effective for pathogen neutralization, explained David Fox, a Los Alamos National Laboratory researcher on the project.

The team examined a panel of in-house synthesized ionic liquids and enabled the discovery of one ionic liquid, choline-geranate, which showed excellent antimicrobial activity, minimal toxicity to epithelial cells as well as skin, and effective permeation enhancement for drug delivery. Choline-geranate increased delivery of cefadroxil, an antibiotic, by 16-fold into the deep tissue layers of the skin without inducing skin irritation.

Source: Los Alamos National Laboratory

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here